Search

Your search keyword '"Alan Ashworth"' showing total 842 results

Search Constraints

Start Over You searched for: Author "Alan Ashworth" Remove constraint Author: "Alan Ashworth"
842 results on '"Alan Ashworth"'

Search Results

1. Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology

2. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo.

3. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer

4. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA

5. Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking

6. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis

7. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers

8. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

9. Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets

10. Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry

11. Smoking and risk of breast cancer in the Generations Study cohort

12. Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study

13. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

15. Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines

18. Chronic mould exposure as a risk factor for severe community acquired pneumonia in a patient requiring extra corporeal membrane oxygenation

20. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

21. Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells

22. Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

23. MicroRNA related polymorphisms and breast cancer risk.

24. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.

25. Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).

26. NLK is a novel therapeutic target for PTEN deficient tumour cells.

27. A modified method for whole exome resequencing from minimal amounts of starting DNA.

29. Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).

30. Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men.

31. Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.

32. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

33. Integrated functional, gene expression and genomic analysis for the identification of cancer targets.

34. Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine.

36. Signalling pathways implicated in early mammary gland morphogenesis and breast cancer.

37. Generation and comparative analysis of an Itga8-CreERT2 mouse with preferential activity in vascular smooth muscle cells

38. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

39. Large tandem duplications in cancer result from transcription and DNA replication collision

40. Generation and Comparative Analysis of an

41. A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo

42. Supplementary Table S1 and Fig S1 and S2 from Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

43. Supplementary Figures 1-10 from Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

45. Supplementary Figures S1-S6 from Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

46. Supplementary Table 1 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

47. Supplementary Video S3 from E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer

49. Supplementary Movie S1 from An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor

50. Supplementary Table 3 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Catalog

Books, media, physical & digital resources